Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Fermer

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
information fournie par Boursorama CP 10/03/2021 à 17:45

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers

- Enrollment of the first patient is expected in Q2 2021
- Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study
- Trial targets indications where clinical outcomes can be improved versus standard therapeutic options and immune checkpoint inhibitors ("ICIs")
- Continued clinical collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to conduct the expanded Phase II study

.../...

Valeurs associées

0,7860 EUR Euronext Paris 0,00%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.